Alphamab Oncology Grants Award Shares to Directors

Alphamab Oncology ( (HK:9966) ) has provided an announcement.

Alphamab Oncology has announced the grant of 120,000 award shares under its Restricted Share Award Scheme to three directors, including one non-executive and two independent non-executive directors. This move is part of the company’s strategy to reward the directors for their contributions and align their interests with the company’s goals. The shares will vest over 24 months and do not have performance targets, which the Remuneration Committee believes is consistent with market practices and the company’s remuneration policy.

The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company based in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company is listed on the Hong Kong Stock Exchange and is involved in creating biologics for oncology treatment.

Average Trading Volume: 4,416,338

Technical Sentiment Signal: Hold

Current Market Cap: HK$8.55B

For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.